Mistie Holly Collins, APRN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 2900 Chancellor Dr, Crestview Hills, KY 41017 Phone: 859-341-0228 Fax: 859-341-7482 |
Miss Sheila Mary Obrien, REGISTERED NURSE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 30 Rosemont Ave, Crestview Hills, KY 41017 Phone: 859-341-0881 |
Meredith Nicole Brueggemann, APRN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 340 Thomas More Pkwy Ste 260, Crestview Hills, KY 41017 Phone: 859-957-0700 Fax: 859-957-0703 |
Matthew Wright, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 340 Thomas More Pkwy Ste 220, Crestview Hills, KY 41017 Phone: 859-301-2211 |
Felicia Marie Hartwell, NP Registered Nurse - General Practice Medicare: Accepting Medicare Assignments Practice Location: 425 Centre View Blvd, Crestview Hills, KY 41017 Phone: 859-341-3575 Fax: 859-341-5072 |
Maribeth E. Hibbett, APRN Registered Nurse - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 334 Thomas More Parkway, Crestview Hills, KY 41017 Phone: 859-301-5901 Fax: 859-301-5940 |
News Archive
BioMS Medical Corp., today announced financial and operational results for the three months ended March 31, 2010.
A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.
The TADS researchers said that major depressive disorder is common, with one in 20 teens affected at varying levels of severity. Like other forms of depression, major depressive disorder has been associated with increased risk of suicidal behavior and with completed suicide.
Marketing is not working well enough to serve the needs of the industry or the changing expectations of the patient. It is time to analyse what we are doing well, and where we need to invest effort and embrace genuine customer engagement. It's time to embrace innovative technologies, improve standard practice and roll out more valuable technologies when justified and create truly integrated, inspiring multichannel engagement campaigns.
Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.
› Verified 3 days ago